+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hemostatic parameters in menstrual fluid and blood plasma during the normal menstrual cycle Cyclic variation of Urokinase-Type Plasminogen Activator



Hemostatic parameters in menstrual fluid and blood plasma during the normal menstrual cycle Cyclic variation of Urokinase-Type Plasminogen Activator



Fibrinolysis & Proteolysis 13(Suppl. 1): 47-48




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035024708

Download citation: RISBibTeXText


Related references

Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thrombosis and Haemostasis 55(3): 388-389, 1986

Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss. Acta Obstetricia et Gynecologica Scandinavica 45(4): 429-450, 1966

Tissue type plasminogen activator and its inhibitor in peritoneal fluid of patients with and without endometriosis at different phases of the menstrual cycle. Fibrinolysis 8(Suppl. 1): 142, 1994

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Histamine concentration in plasma of menstrual and peripheral blood from patients with normal menstrual blood loss and in dysfunctional menstrual bleeding. International Journal of Gynecology & Obstetrics (ABSTR Suppl.): 501, 1991

Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator). Blood Coagulation & Fibrinolysis 7(8): 766-771, 1996

Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Molecular Human Reproduction 10(9): 655-663, 2004

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single scu pa or two chain urokinase type plasminogen activator tcu pa by a combined assay system for urokinase type plasminogen activator antigen and function. Thrombosis & Haemostasis 61(2): 289-293, 1989

Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thrombosis and Haemostasis 56(1): 35-39, 1986

Absence of synergism between tissue type plasminogen activator single chain urokinase type plasminogen activator and urokinase on clot lysis in a plasma milieu in vitro. Thrombosis & Haemostasis 56(1): 35-39, 1986

Expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in synovial fluid of patients with temporomandibular disorders. Zhonghua Kou Qiang Yi Xue Za Zhi 43(3): 160-163, 2008

Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 23(8): 478-481, 2012

Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecologic Oncology 79(2): 244-250, 2000